Literature DB >> 9973437

Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.

C Castelli1, P Tarsini, A Mazzocchi, F Rini, L Rivoltini, F Ravagnani, F Gallino, F Belli, G Parmiani.   

Abstract

The identification of T cell epitopes presented by alternative HLA-B and -C alleles may provide a means to counteract the tumor escape mechanism based on the selection of tumor cells no longer susceptible to HLA-A-restricted T cell recognition. Several T cell clones and lines were obtained from T lymphocytes purified from melanoma-infiltrated or noninfiltrated lymph nodes of a patient who remained disease free 8 yr after surgery. Selected T cells recognized the autologous melanoma as evaluated by direct cytolysis and production of cytokines. These effectors were directed against the tyrosinase-related protein-2 (TRP-2) and gp100 melanoma epitopes restricted by HLA-Cw8. The nonamer and decamer peptides containing the sequence ANDPIFVVL (residues 387-395) of TRP-2 and the octamer, nonamer, and decamer peptides containing the sequence SNDGPTLI (residues 71-78) of gp100 reconstituted the epitope for TRP-2- and gp100-specific T cell lines and clones, respectively. However, only the nonameric form of TRP-2 and the nonameric and octameric forms of gp100 were able to induce peptide-specific T cells recognizing the autologous tumor in an HLA-class I-restricted fashion from PBMC of the melanoma patient studied. Together these data indicate that HLA-Cw8 can restrict the recognition of gp100 and TRP-2 epitopes by CTL, and that such peptides could stimulate a patient's PBL, suggesting that these Ags could have contributed to a systemic immunity against melanoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973437

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats.

Authors:  Sarah E Nichols; Dawn C Harper; Joanne F Berson; Michael S Marks
Journal:  J Invest Dermatol       Date:  2003-10       Impact factor: 8.551

2.  Identification of HLA-Cw6.02 and HLA-Cw7.01 allele-specific binding motifs by screening synthetic peptide libraries.

Authors:  Sara O Dionne; Douglas F Lake; William J Grimes; Margaret H Smith
Journal:  Immunogenetics       Date:  2004-08-12       Impact factor: 2.846

Review 3.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

Review 4.  Immune targets and neoantigens for cancer immunotherapy and precision medicine.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

Review 5.  Peptide epitope identification for tumor-reactive CD4 T cells.

Authors:  Hiroya Kobayashi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2008-05-20       Impact factor: 7.486

Review 6.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Authors:  Darryl A Oble; Robert Loewe; Ping Yu; Martin C Mihm
Journal:  Cancer Immun       Date:  2009-04-02

7.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

Authors:  David Escors
Journal:  New J Sci       Date:  2014-01-05

Review 8.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.